NCT02791490View on ClinicalTrials.gov

A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)

PHASE3CompletedINTERVENTIONAL
Enrollment

458

Participants

Timeline

Start Date

June 16, 2016

Primary Completion Date

February 1, 2018

Study Completion Date

February 1, 2018

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Sitagliptin

Oral tablet, 100 mg, once daily at approximately the same time each day

DRUG

Placebo

Oral tablet, once daily at approximately the same time each day

DRUG

Metformin IR

All participants will take Met-IR as background medication. Initially, they will take 1 x 500 mg tablet Met-IR b.i.d. (1000 mg/day). After randomization, all participants will be titrated to 2 x 500 mg tablets of Met-IR b.i.d. (2000 mg/day).

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02791490 - A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848) | Biotech Hunter | Biotech Hunter